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| INTRODUC TI ON
The average adult produces approximately 2.4 million new red blood cells (RBCs) every second. These cells are rich in hemoglobin (Hb), an iron-containing protein that is responsible for the oxygen supply to the tissues. The RBC membrane is composed of proteins and lipids and provides properties essential for physiological cell function, as deformability and stability while traversing the circulatory system and specifically the capillary network. Mature RBCs lack the nucleus and most organelles, to accommodate maximum space for Hb.
There are precise homeostatic mechanisms to ensure sufficient, but not excess, RBC production. Any imbalance in the homeostatic mechanisms can lead to anemia or to excess of RBCs production, known as erythrocytosis.
Erythrocytosis corresponds to an increase in the RBC count, Hb concentration, and hematocrit (Hct) above the reference range (adjusted to age, sex and living altitude), due to the expansion of the erythrocyte compartment in the peripheral blood.
Absolute erythrocytosis occurs when the RBC mass is >125% of that predicted or when a raised Hb and Hct (Hb >185 g/L or a Hct > 0.52 in a male and a Hb > 165 g/L or Hct > 0.48 in the female) is observed in at least 2 separate blood counts performed at different time points. Absolute erythrocytosis is distinct from relative erythrocytosis, which is caused by a severe plasma volume reduction (eg, due to diuretics or severe diarrhea) and distinct from apparent erythrocytosis, caused by arterial hypoxemia (eg, cigarette smoking, carbon monoxide poisoning, or sleep apnea).
Based on pathophysiology, absolute erythrocytosis can be classified as either primary or secondary erythrocytosis, which can be of either congenital or acquired origin (Table 1) .
| Primary erythrocytosis
Primary erythrocytosis is a condition in which there is an intrinsic defect in the erythroid precursor cells. Primary erythrocytosis is usually characterized by low serum EPO levels and hypersensitivity of erythroid progenitors to EPO. 5, 6 Acquired primary erythrocytosis is due to polycythemia vera (PV), where erythroid progenitors carry a gain-of-function mutation in JAK2, which leads to constitutive activation of the EPO signaling pathway at the EPOR level. Somatic JAK2 V617F and JAK2 exon 12 mutations are responsible for 98% of the cases described. 
| Idiopathic erythrocytosis
Erythrocytosis in patients with no identified causes is designated idiopathic erythrocytosis (IE). In current practice, the etiology of 70% 
| MOLECUL AR E TI OLOGY AND CLINIC AL MANIFE S TATIONS
Presently, eight genes are known to be associated with CE: EPOR, EGLN1, EPAS1, VHL, HBB, HBA1, HBA2, and BPGM (Table 2) . 12 As mutations in these genes were identified only in 30%-40% of all known CE patients, it can be anticipated that additional genes should be implicated.
| Congenital erythrocytosis type 1 (ECYT 1)
Gain-of-function mutations in the EPOR gene result in PFCP, also known as CE type 1, (ECYT1; OMIM 133100).
The first mutation described in EPOR was in a Finnish family. 13 Since then, several mutations have been described in association with CE, all located in exon 8, which encodes the C-terminal negative regulatory domain of the protein. Transmission is autosomal dominant, with some cases arising de novo.
Whereas the majority of adult patients with EPOR mutations had only mild symptoms, some cases were reported to present with severe and even fatal clinical complications such as arterial hypertension, intracerebral hemorrhage, deep vein thrombosis, coronary disease, and myocardial infarction. In the majority of patients, no regular treatment is needed, and some patients could be controlled by antihypertensive treatment and by phlebotomies, when they either present hyperviscosity symptoms or regularly performed aimed to maintain the hematocrit at an almost normal level. 14 
| Congenital erythrocytosis type 2 (ECYT 2)
The first loss-of-function mutation described in the VHL gene associated with CE was found in the Chuvash autonomous republic of Russia where erythrocytosis is an endemic disorder. Chuvash polycythemia was found to be caused by a homozygous mutation VHL c.598C>T (p.Arg200Trp; R200W) 15 arisen from a single founding or single mutation event occurring 14 000 to 50 000 years ago. 16 Later, the VHL c.598C>T and other VHL mutations were observed in non-Chuvash patients, in the homozygous or compound heterozygous state, in association with CE type 2 (ECYT2; OMIM 263400).
Although CE type 2 is considered a recessive disease, the occurrence of patients heterozygous for VHL mutations with erythrocytosis has been described. 
| Congenital erythrocytosis type 3 (ECYT 3)
Loss-of-function mutations in EGLN1 cause CE type 3 (ECYT3;
OMIM 609820), with autosomal-dominant inheritance. 
| Congenital erythrocytosis type 4 (ECYT4)
Gain-of-function mutations in EPAS1 gene are responsible for erythrocytosis type 4 (ECYT4, OMIM 611783), with an autosomal-dominant inheritance.
Nine heterozygous mutations have been identified in exon 12 of the EPAS1 gene, leading to HIF-2α variants. The majority of these missense mutations is located close to 1 of the 2 hydroxylated proline residues (Pro531) in HIF-2α and may reduce both hydroxylation of HIF-2α by the PHDs and subsequent recognition of HIF-2α by pVHL. These variants are linked with erythrocytosis, and in all cases, patients were diagnosed with elevated EPO levels.
| Hb variants with increased O 2 affinity
The first described molecular defect associated with CE was in an Most of the high-affinity Hb variants described thus far have sub- As erythrocytosis in these patients is primarily a requirement due to general tissue hypoxia, phlebotomy treatment should be limited to single symptomatic event.
Cases have been described showing unusual incidences of spontaneous abortion in female carriers caused by the lower oxygenation of the fetus resulting from either the alteration in the physiological O 2 gradient affinity between fetal and maternal blood or by placental infarction caused by the high viscosity of the mother's blood. Reported cases in the literature of CE due to BPGM mutations are very rare with only 3 cases described.
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| Clinical presentation and follow-up
Patients with CE are frequently young, either a child or a young adult,
given that these are congenital disorders, in contrast to patients with classic myeloproliferative neoplasms who typically present at much older ages. The only sizeable cohort of patients with congenital erythrocytosis are the VHL R200W homozygotes, first described in the Chuvash region of Russia. Chuvash patients had a more thrombosis and reduced life expectancy than normal controls, with increased venous varicosity.
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Erythrocytosis patients need long-term follow-up by a hematologist in order to continue to review the need for treatment and to record any events and outcomes. As it is a very rare disease, it would be helpful if data on such patients could be entered into international databases so that more information on long-term outcomes is amassed.
| D IAG NOS IS
When diagnosing a patient with erythrocytosis, it is important to exclude acquired secondary (eg, pulmonary, renal and cardiac) or acquired primary (eg, PV) causes.
The family history and the quantification of serum EPO are mandatory to define the best diagnostic strategy regarding molecular studies. According to published data, the high-affinity Hbs are the commonest causes of secondary congenital erythrocytosis. We propose that in individuals with a dominant form of erythrocytosis and normal or high EPO levels, the determination of P50 should be done as a first line diagnosis. Sequencing of the candidate genes is mandatory for a definitive diagnosis. Based upon the serum EPO level, P50, and familial data, it is possible to establish a diagnostic algorithm (Figure 1) . A comparable diagnostic algorithm for children and adolescents has been published by members of the MPN&MPNr-EuroNet. 
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They found at least one pathogenic variant in 57 of the 125 patients studied, reducing the number of patients without a molecular cause identified to 54%. Surprisingly, in 29% of patients, the variant found was in one of the already known genes.
As targeted NGS is cost-efficient and provides rapid and accurate mutation analysis, this approach could be applied directly to erythrocytosis cases where a genetic cause is suspected. 26 
| CON CLUS ION
Significant advances have been made during the past decade in the CE field with the identification of causal mutations in the EPOR gene and the elucidation of the genes directly implicated in the hypoxiasensing mechanism. Presently, eight genes have been associated with CE, but despite this, the majority of patients remain without a diagnosis. The lack of a diagnosis can have considerable adverse effects for patients and their families, including failure to identify potential treatments, failure to recognize the risk of recurrence in subsequent pregnancies, and failure to provide anticipatory guidance and prognosis.
We hope that the use of high-throughput technology as targeted sequencing panels and WGS will be a useful tool in the identification of novel variants and candidate genes associated with the development of congenital erythrocytosis.
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